Express Scripts, Inc. v. Bracket Holdings Corp

CourtSupreme Court of Delaware
DecidedFebruary 23, 2021
Docket62, 2020
StatusPublished

This text of Express Scripts, Inc. v. Bracket Holdings Corp (Express Scripts, Inc. v. Bracket Holdings Corp) is published on Counsel Stack Legal Research, covering Supreme Court of Delaware primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Express Scripts, Inc. v. Bracket Holdings Corp, (Del. 2021).

Opinion

IN THE SUPREME COURT OF THE STATE OF DELAWARE

EXPRESS SCRIPTS, INC. and § UNITED BIOSOURCE LLC, § No. 62, 2020 § Defendants Below, § Court Below: Superior Court Appellants/Cross- § of the State of Delaware Appellees, § § C.A. No. N15C-02-233 CCLD v. § § BRACKET HOLDINGS CORP., § § Plaintiff Below, § Appellee/Cross- § Appellant.

Submitted: December 16, 2020 Decided: February 23, 2021

Before SEITZ, Chief Justice; VALIHURA, VAUGHN, TRAYNOR, and MONTGOMERY-REEVES, Justices, constituting the Court en Banc.

Upon appeal from the Superior Court. REVERSED and REMANDED.

Kevin G. Abrams, Esquire, Michael A. Barlow, Esquire, Daniel J. McBride, Esquire, ABRAMS & BAYLISS LLP, Wilmington, Delaware; Derek L. Shaffer, Esquire (argued), Michael Lyle, Esquire, QUINN EMANUEL URQUHART & SULLIVAN, LLP, Washington, D.C., Richard I. Werder, Jr., Esquire, Rollo C. Baker, Esquire, Silpa Maruri, Esquire, Dominic J. Pody, Esquire, QUINN EMANUEL URQUHART & SULLIVAN, LLP, New York, New York; Attorneys for Defendants-Appellants/Cross-Appellees Express Scripts, Inc. and United BioSource LLC.

David E. Ross, Esquire, Eric D. Selden, Esquire, ROSS ARONSTAM & MORITZ LLP, Wilmington, Delaware; Paul D. Clement, Esquire (argued), C. Harker Rhodes IV, KIRKLAND & ELLIS LLP, Washington, D.C.; Kevin M. Neylan, Jr., Esquire, KIRKLAND & ELLIS LLP, New York, New York; Attorneys for Plaintiff- Appellee/Cross-Appellant Bracket Holdings Corp. SEITZ, Chief Justice:

United BioSource LLC (“UBC”), a subsidiary of Express Scripts, Inc. (“ESI”)

agreed to sell three of UBC’s pharmaceutical research and development businesses

to Bracket Holding Corp. (“Bracket”), a holding company formed by Parthenon

Capital Partners, LP (“Parthenon”) for the acquisition. In August 2013, Bracket and

UBC signed a $187 million securities purchase agreement (the “SPA”). Except for

claims involving deliberate fraud and certain fundamental representations, Bracket

agreed to limit its remedy for breach of the SPA’s representations and warranties to

an insurance policy (the “R&W Policy”) purchased to cover these claims.

After closing, Bracket claimed that ESI and UBC engaged in fraud by

inflating the revenue and working capital of one of the divisions of the acquired

companies. In an arbitration proceeding Bracket recovered $13 million under the

R&W Policy for breach of the SPA’s representations and warranties. Bracket then

sued ESI and UBC for fraud in the Superior Court. A jury awarded Bracket over

$82 million.

The parties have appealed from the jury verdict and judgment. We find one

issue dispositive. The SPA provides unambiguously that, except in the case of

deliberate fraud and certain fundamental representations, Bracket could only recover

up to the R&W Policy’s limits for breaches of the representations and warranties.

Over ESI’s objection, however, the Superior Court instructed the jury that it could

2 find for Bracket not only for deliberate fraud, but also for recklessness. A deliberate

state of mind is a different kettle of fish than a reckless one. The court’s erroneous

jury instruction was not harmless—it violated a key provision of the SPA and how

the parties allocated risk in the transaction. We therefore reverse the Superior

Court’s judgment and remand for a new trial. To be helpful to the court and the

parties on remand, we also address one other meritorious issue raised by ESI and

UBC in their appeal.

I.

We review the facts in a light most favorable to the jury’s verdict.1 ESI is a

Delaware corporation providing pharmaceutical support services and benefits

management. In 2012, ESI acquired UBC and its three subsidiaries—Bracket

Global Holdings LLC, Bracket Global K.K., and Bracket Global Limited.

Parthenon, a private equity fund, formed Bracket to purchase the Company from

UBC. To distinguish between Bracket Holding Corp., the acquisition entity, and the

three UBC Bracket subsidiaries, we will refer to the acquisition entity as “Bracket”

and the three subsidiaries as the “Company.” We will also refer to ESI and UBC

together as “the defendants.”

1 Burgos v. Hickok, 695 A.2d 1141, 1142 (Del. 1997). Unless otherwise stated, the facts are drawn from the Superior Court’s opinion, In re Bracket Hldg. Corp. Litig., 2020 WL 764148 (Del. Super. Ct. Feb. 7, 2020). 3 In the fall of 2012, UBC hired Credit Suisse Securities (USA) LLC (“Credit

Suisse”) as its financial advisor to market the Company and KPMG LLC (“KPMG”)

to perform sell-side due diligence. Credit Suisse prepared a Confidential

Information Memorandum (“CIM”), while KPMG conducted a Quality of Earnings

(“QoE”) investigation, which led to a February 2013 QoE Report. After Parthenon

received both reports, it submitted a letter of intent to purchase the Company. To

price the transaction, Parthenon focused on a multiple to the Company’s Earnings

Before Interest, Taxes, Depreciation, and Amortization—“EBITDA” in the twelve-

month period prior to closing (“TTM EBITDA”).

During due diligence, Parthenon grew concerned about the high balance of

unbilled accounts in the QoE Report for Scientific Services, one of the Company’s

divisions. It raised the issue with Jim Stewart, the Company’s Vice President of

Finance. Stewart responded that the high receivable balance came from contract

change orders when additional work was authorized beyond the scope of the original

contract but had not yet been reflected in a revised contract. According to Stewart,

unexecuted change orders were common in the industry and did not pose

collectability problems. KPMG did not express concerns about the collectability of

the balances.

On July 12, 2013, Bracket and UBC entered the SPA. UBC represented that

the January 2011 through March 2013 financial information in the disclosure

4 schedule supporting a $29 million TTM EBITDA was true and correct. UBC also

represented that, as of May 31, 2013, the Company had $11.85 million in working

capital, subject to a post-closing adjustment.

Soon after closing, Bracket believed it had been misled about the Company’s

finances. According to Bracket, the Company had inflated historical revenue by

millions of dollars. The Company’s unbilled receivable balance was way off.

Contracts did not support the balances and the revenue recognized against them. The

Company recognized revenue long after work ended. Revenue continued to be

booked for closed out contracts and was uncollectible. Bracket claimed that the

Company’s working capital was a negative $2.7 million along with large unbilled

receivables.

After some back and forth between the parties, Bracket settled on a negative

$14 million in working capital, requiring an over $25 million post-closing working

capital adjustment. Bracket attributed the shortfalls to overstated unbilled

receivables. Bracket also believed that it overpaid for the Company by tens of

millions of dollars based on the effect unbilled receivables had on revenue.

In October 2014, Bracket demanded arbitration to recover under the R&W

Policy. The arbitration raised many of the same events that led to this litigation.

Bracket recovered $13 million under the R&W Policy. The defendants did not

participate in the arbitration.

5 In 2015, UBC filed an action in the Court of Chancery to compel Bracket to

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Hinojosa v. Butler
547 F.3d 285 (Fifth Circuit, 2008)
Daniels v. Williams
474 U.S. 327 (Supreme Court, 1986)
Staub v. Proctor Hospital
131 S. Ct. 1186 (Supreme Court, 2011)
Lorillard Tobacco Co. v. American Legacy Foundation
903 A.2d 728 (Supreme Court of Delaware, 2006)
Duphily v. Delaware Electric Cooperative, Inc.
662 A.2d 821 (Supreme Court of Delaware, 1995)
Airborne Health, Inc. v. Squid Soap, LP
984 A.2d 126 (Court of Chancery of Delaware, 2009)
Koutoufaris v. Dick
604 A.2d 390 (Supreme Court of Delaware, 1992)
Sammons v. Doctors for Emergency Services, P.A.
913 A.2d 519 (Supreme Court of Delaware, 2006)
Burgos Ex Rel. Burgos v. Hickok
695 A.2d 1141 (Supreme Court of Delaware, 1997)
E.I. DuPont De Nemours & Co. v. Pressman
679 A.2d 436 (Supreme Court of Delaware, 1996)
Stevenson v. State
709 A.2d 619 (Supreme Court of Delaware, 1998)
Abry Partners V, L.P. v. F & W Acquisition LLC
891 A.2d 1032 (Court of Chancery of Delaware, 2006)
Culver v. Bennett
588 A.2d 1094 (Supreme Court of Delaware, 1991)
Riggins v. Mauriello
603 A.2d 827 (Supreme Court of Delaware, 1992)
Kiser v. State
769 A.2d 736 (Supreme Court of Delaware, 2001)
DCV Holdings, Inc. v. ConAgra, Inc.
889 A.2d 954 (Supreme Court of Delaware, 2005)
Tydings v. Loewenstein
505 A.2d 443 (Supreme Court of Delaware, 1986)
Spencer v. Wal-Mart Stores East, LP
930 A.2d 881 (Supreme Court of Delaware, 2007)

Cite This Page — Counsel Stack

Bluebook (online)
Express Scripts, Inc. v. Bracket Holdings Corp, Counsel Stack Legal Research, https://law.counselstack.com/opinion/express-scripts-inc-v-bracket-holdings-corp-del-2021.